172 related articles for article (PubMed ID: 37565529)
1. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half-life (EHL) factor products: A 12-month data analysis.
George C; Parikh S; Carter T; Mccosker J; Carlino S; Tran H
Haemophilia; 2023 Sep; 29(5):1283-1290. PubMed ID: 37565529
[TBL] [Abstract][Full Text] [Related]
2. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
4. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
5. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
[TBL] [Abstract][Full Text] [Related]
6. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Lehtinen AE; Baghaei F; Astermark J; Holme PA
Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
[TBL] [Abstract][Full Text] [Related]
9. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B.
Chhabra A; Spurden D; Fogarty PF; Tortella BJ; Rubinstein E; Harris S; Pleil AM; Mellor J; de Courcy J; Alvir J
Blood Coagul Fibrinolysis; 2020 Apr; 31(3):186-192. PubMed ID: 32271314
[TBL] [Abstract][Full Text] [Related]
12. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
14. Haemophilia joint health score (HJHS) usage, patterns and outcome data in patients with haemophilia A and haemophilia B in Australia: A descriptive study using the Australian Bleeding Disorders Registry (ABDR).
George C; Parikh S; Carter T; Morris A; Cramey C; Mcelroy K; Tran H
Haemophilia; 2023 Jul; 29(4):1135-1141. PubMed ID: 37335559
[TBL] [Abstract][Full Text] [Related]
15. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia.
Skinner MW; Dolan G; Eichler H; O'Mahony B;
Haemophilia; 2022 Mar; 28 Suppl 2():9-18. PubMed ID: 35318780
[TBL] [Abstract][Full Text] [Related]
16. Perceptions about the efficacy of extended half-life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States.
Swaminathan N; Salinas-Luna V; Acharya S; Sharathkumar A
Haemophilia; 2021 Nov; 27(6):e780-e783. PubMed ID: 34592042
[No Abstract] [Full Text] [Related]
17. The long and short of it: using the new factor products.
Dunn A
Hematology Am Soc Hematol Educ Program; 2015; 2015():26-32. PubMed ID: 26637697
[TBL] [Abstract][Full Text] [Related]
18. [Haemophilia A and haemophilia B. Are there relevant clinical differences?].
Klamroth R; Orlovic M; Kubicek-Hofman C; Gottstein S
Hamostaseologie; 2010 Nov; 30 Suppl 1():S26-7. PubMed ID: 21042678
[TBL] [Abstract][Full Text] [Related]
19. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study.
Kihlberg K; Baghaei F; Bruzelius M; Funding E; Andre Holme P; Lassila R; Nummi V; Ranta S; Osooli M; Berntorp E; Astermark J
Haemophilia; 2021 May; 27(3):366-374. PubMed ID: 33780113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
